BMN 270
Biological
BioMarin Pharmaceutical Inc.
Total Payments
$981,035
Transactions
188
Doctors
27
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $967,109 | 138 | 15 |
| 2017 | $13,926 | 50 | 15 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $950,970 | 107 | 96.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,425 | 16 | 1.6% |
| Consulting Fee | $5,500 | 4 | 0.6% |
| Travel and Lodging | $4,545 | 16 | 0.5% |
| Food and Beverage | $3,430 | 34 | 0.3% |
| Education | $1,165 | 11 | 0.1% |
Payments by Type
Research
$950,970
107 transactions
General
$30,065
81 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients | BioMarin Pharmaceutical Inc. | $486,875 | 0 |
| A Prospective Non-Interventional Study of Bleeding Episodes, Factor VIII Infusions, and Patient-Reported Outcomes in Individuals with Severe Hemophilia A | BioMarin Pharmaceutical Inc. | $277,969 | 0 |
| A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus VectorMediated Gene Transfer of Human Factor VIII at a dose of 4E13 vgkg in Hemophilia A Patients with Residual FVIII Levels 1 IUdL Recei | BioMarin Pharmaceutical Inc. | $112,172 | 0 |
| Global Prospective Laboratory Study for Adenovirus-Associated Virus AAV Seroprevalence in Hemophilia A Patients with Residual Factor VIII Levels 2 IUdL Who Were Previously Treated with Factor VIII Concentrates | BioMarin Pharmaceutical Inc. | $73,953 | 0 |
Ad
Manufacturing Companies
- BioMarin Pharmaceutical Inc. $981,035
Product Information
- Type Biological
- Total Payments $981,035
- Total Doctors 27
- Transactions 188
About BMN 270
BMN 270 is a biological associated with $981,035 in payments to 27 healthcare providers, recorded across 188 transactions in the CMS Open Payments database. The primary manufacturer is BioMarin Pharmaceutical Inc..
Payment data is available from 2017 to 2018. In 2018, $967,109 was paid across 138 transactions to 15 doctors.
The most common payment nature for BMN 270 is "Unspecified" ($950,970, 96.9% of total).
BMN 270 is associated with 4 research studies, including "Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients" ($486,875).